Currently, clinical trials are assessing the efficacy of anti-IL-33 monoclonal antibody treatments (Itepekimab, Etokimab and Tozorakimab) in chronic obstructive pulmonary disease, asthma, atopic dermatitis and peanut allergy [127–130]. This evidence concerns the gene IL33 and peanut allergic reaction.